Type of Action: RIA
Duration: 24 months
Start date: 1st January 2018
Grant agreement: 777554
Web: (not yet available)
Total request Grant by Consortium: € 3,000,000.-
Total request Grant by BBMRI-ERIC: € 192,500.-
Linked Third Parties/BBMRI-ERIC Framework Agreement: UNIMIB, University of Milano-Bicocca
Benefit/tasks for BBMRI-ERIC: Managing a thematic platform that aims to create ideal conditions for the development and use of paediatric biomarkers, with particular emphasis on enhancing the potential of -omics science in paediatrics.
EPTRI is aimed at harnessing the research and services for the development of medicines for children as well as identifying gaps in paediatric medicines research preventing efficient use of research technologies across pertinent medicine research fields, from discovery and preclinical phase, all the way to ameliorate the therapeutic use of medicines in clinical practice. Sharing understanding of patients’ needs and concerted efforts in critical areas of research will end in further enhancing the health of children and will also have a positive impact on European competitiveness in the pharmaceutical sector.
The new RI (EPTRI) will integrate the critical mass of competencies and structures in the paediatric research sector and the consolidated efforts of scientific groups, Networks of Excellence, Research Consortia, specialty Networks to provide ‘facilities, resources and related services’ to be used by the large scientific community to conduct top-level research in their respective fields of activity. Our final aim is to realise an integrated system which has never been developed in a so structured and comprehensive way in order to bring together all these paediatric activities and the technologies with a big impact on preparing clinical research in so producing a huge acceleration/qualification of procedures for development of new medicines.